在一项大规模肺部病变回顾性研究中质疑基于 SUV 的参数的意义。

IF 3.5 2区 医学 Q2 ONCOLOGY
Cristiano Pini, Margarita Kirienko, Fabrizia Gelardi, Paola Bossi, Daoud Rahal, Luca Toschi, Gaia Ninatti, Marcello Rodari, Giuseppe Marulli, Lidija Antunovic, Arturo Chiti, Emanuele Voulaz, Martina Sollini
{"title":"在一项大规模肺部病变回顾性研究中质疑基于 SUV 的参数的意义。","authors":"Cristiano Pini, Margarita Kirienko, Fabrizia Gelardi, Paola Bossi, Daoud Rahal, Luca Toschi, Gaia Ninatti, Marcello Rodari, Giuseppe Marulli, Lidija Antunovic, Arturo Chiti, Emanuele Voulaz, Martina Sollini","doi":"10.1186/s40644-024-00807-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although many well-known factors affect the maximum standardized uptake value (SUVmax), it remains the most requested and used parameter, especially among clinicians, despite other parameters, such as the standardized uptake value corrected for lean body mass and the metabolic tumor volume, being proven to be less sensitive to the same factors, more robust, and eventually more informative. This study intends to provide robust evidence regarding the diagnostic and prognostic value of SUVmax in a large cohort of subjects with suspected malignant lung nodules imaged by [<sup>18</sup>F]FDG PET/CT.</p><p><strong>Materials and methods: </strong>We performed a retrospective analysis of patients with suspected/confirmed primary lung tumours undergoing [18F]FDG PET/CT. The sample size was 567 patients. Demographics, imaging, surgical, histological, and follow-up data were collected. SUVmax was analysed according to histology, stage, scanner, and outcome. The impact on measured values of different reconstruction protocols was assessed. All potential predictors of patients' outcome were assessed.</p><p><strong>Results: </strong>91% cases were primary lung tumours. Lung benign nodules or metastases accounted for 5% and 4% of cases. Most patients presented with adenocarcinoma (70%) and stage I disease (51%); 144 patients relapsed and 55 died. SUVmax failed to effectively differentiate benign lesions from primary tumours or metastases. Stage I patients presented lower SUVmax. SUVmax significantly correlated with patient weight, injected [<sup>18</sup>F]FDG activity, and lesion size and differed between reconstructions' protocols. Survival analyses revealed no independent prognostic significance for SUVmax in progression-free after adjusting for other variables. SUVmax correlated with overall survival, disease stage and tumour histotype.</p><p><strong>Conclusion: </strong>Our study confirms that SUVmax, though widely employed, present relevant limitations in discriminating between benign lesion and lung cancer, in classifying cancer histotypes, and in predicting patient outcomes independently. Known influencing factors significantly impact on numerical values, thus SUV values should be regarded with caution in clinical practice.</p>","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"24 1","pages":"162"},"PeriodicalIF":3.5000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600847/pdf/","citationCount":"0","resultStr":"{\"title\":\"Challenging the significance of SUV-based parameters in a large-scale retrospective study on lung lesions.\",\"authors\":\"Cristiano Pini, Margarita Kirienko, Fabrizia Gelardi, Paola Bossi, Daoud Rahal, Luca Toschi, Gaia Ninatti, Marcello Rodari, Giuseppe Marulli, Lidija Antunovic, Arturo Chiti, Emanuele Voulaz, Martina Sollini\",\"doi\":\"10.1186/s40644-024-00807-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Although many well-known factors affect the maximum standardized uptake value (SUVmax), it remains the most requested and used parameter, especially among clinicians, despite other parameters, such as the standardized uptake value corrected for lean body mass and the metabolic tumor volume, being proven to be less sensitive to the same factors, more robust, and eventually more informative. This study intends to provide robust evidence regarding the diagnostic and prognostic value of SUVmax in a large cohort of subjects with suspected malignant lung nodules imaged by [<sup>18</sup>F]FDG PET/CT.</p><p><strong>Materials and methods: </strong>We performed a retrospective analysis of patients with suspected/confirmed primary lung tumours undergoing [18F]FDG PET/CT. The sample size was 567 patients. Demographics, imaging, surgical, histological, and follow-up data were collected. SUVmax was analysed according to histology, stage, scanner, and outcome. The impact on measured values of different reconstruction protocols was assessed. All potential predictors of patients' outcome were assessed.</p><p><strong>Results: </strong>91% cases were primary lung tumours. Lung benign nodules or metastases accounted for 5% and 4% of cases. Most patients presented with adenocarcinoma (70%) and stage I disease (51%); 144 patients relapsed and 55 died. SUVmax failed to effectively differentiate benign lesions from primary tumours or metastases. Stage I patients presented lower SUVmax. SUVmax significantly correlated with patient weight, injected [<sup>18</sup>F]FDG activity, and lesion size and differed between reconstructions' protocols. Survival analyses revealed no independent prognostic significance for SUVmax in progression-free after adjusting for other variables. SUVmax correlated with overall survival, disease stage and tumour histotype.</p><p><strong>Conclusion: </strong>Our study confirms that SUVmax, though widely employed, present relevant limitations in discriminating between benign lesion and lung cancer, in classifying cancer histotypes, and in predicting patient outcomes independently. Known influencing factors significantly impact on numerical values, thus SUV values should be regarded with caution in clinical practice.</p>\",\"PeriodicalId\":9548,\"journal\":{\"name\":\"Cancer Imaging\",\"volume\":\"24 1\",\"pages\":\"162\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600847/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40644-024-00807-3\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40644-024-00807-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:尽管许多众所周知的因素会影响最大标准化摄取值(SUVmax),但它仍然是最需要和最常用的参数,尤其是在临床医生中,尽管其他参数,如根据瘦体重校正的标准化摄取值和代谢肿瘤体积,已被证明对相同因素的敏感性更低、更稳健、最终信息量更大。本研究旨在为一大批通过[18F]FDG PET/CT 成像的疑似恶性肺结节患者提供有关 SUVmax 诊断和预后价值的可靠证据:我们对接受[18F]FDG PET/CT 检查的疑似/确诊原发性肺肿瘤患者进行了回顾性分析。样本量为 567 例患者。我们收集了患者的人口统计学、影像学、外科、组织学和随访数据。SUVmax根据组织学、分期、扫描仪和结果进行分析。评估了不同重建方案对测量值的影响。评估了患者预后的所有潜在预测因素:91%的病例为原发性肺肿瘤。肺部良性结节或转移瘤分别占5%和4%。大多数患者表现为腺癌(70%)和I期疾病(51%);144名患者复发,55名患者死亡。SUVmax 无法有效区分良性病变与原发肿瘤或转移瘤。I期患者的SUVmax较低。SUVmax与患者体重、注射的[18F]FDG活性和病灶大小有明显相关性,不同的重建方案之间也存在差异。生存分析表明,在调整其他变量后,SUVmax 对无进展预后没有独立意义。SUVmax与总生存期、疾病分期和肿瘤组织型相关:我们的研究证实,SUVmax虽然被广泛应用,但在区分良性病变和肺癌、癌症组织类型分类以及独立预测患者预后方面存在相关局限性。已知的影响因素会对数值产生重大影响,因此在临床实践中应谨慎看待 SUV 值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Challenging the significance of SUV-based parameters in a large-scale retrospective study on lung lesions.

Background: Although many well-known factors affect the maximum standardized uptake value (SUVmax), it remains the most requested and used parameter, especially among clinicians, despite other parameters, such as the standardized uptake value corrected for lean body mass and the metabolic tumor volume, being proven to be less sensitive to the same factors, more robust, and eventually more informative. This study intends to provide robust evidence regarding the diagnostic and prognostic value of SUVmax in a large cohort of subjects with suspected malignant lung nodules imaged by [18F]FDG PET/CT.

Materials and methods: We performed a retrospective analysis of patients with suspected/confirmed primary lung tumours undergoing [18F]FDG PET/CT. The sample size was 567 patients. Demographics, imaging, surgical, histological, and follow-up data were collected. SUVmax was analysed according to histology, stage, scanner, and outcome. The impact on measured values of different reconstruction protocols was assessed. All potential predictors of patients' outcome were assessed.

Results: 91% cases were primary lung tumours. Lung benign nodules or metastases accounted for 5% and 4% of cases. Most patients presented with adenocarcinoma (70%) and stage I disease (51%); 144 patients relapsed and 55 died. SUVmax failed to effectively differentiate benign lesions from primary tumours or metastases. Stage I patients presented lower SUVmax. SUVmax significantly correlated with patient weight, injected [18F]FDG activity, and lesion size and differed between reconstructions' protocols. Survival analyses revealed no independent prognostic significance for SUVmax in progression-free after adjusting for other variables. SUVmax correlated with overall survival, disease stage and tumour histotype.

Conclusion: Our study confirms that SUVmax, though widely employed, present relevant limitations in discriminating between benign lesion and lung cancer, in classifying cancer histotypes, and in predicting patient outcomes independently. Known influencing factors significantly impact on numerical values, thus SUV values should be regarded with caution in clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer Imaging
Cancer Imaging ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CiteScore
7.00
自引率
0.00%
发文量
66
审稿时长
>12 weeks
期刊介绍: Cancer Imaging is an open access, peer-reviewed journal publishing original articles, reviews and editorials written by expert international radiologists working in oncology. The journal encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations. Topics of interest include: Breast Imaging Chest Complications of treatment Ear, Nose & Throat Gastrointestinal Hepatobiliary & Pancreatic Imaging biomarkers Interventional Lymphoma Measurement of tumour response Molecular functional imaging Musculoskeletal Neuro oncology Nuclear Medicine Paediatric.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信